AU Patent

AU2019384119B8 — Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Assigned to Amgen Inc · Expires 2025-03-06 · 1y expired

What this patent protects

The present invention provides combination therapy that includes an KRAS

USPTO Abstract

The present invention provides combination therapy that includes an KRAS

Drugs covered by this patent

Lumakras (SOTORASIB) · Amgen

Patent Metadata

Patent number: AU2019384119B8
Jurisdiction: AU
Classification: —
Expires: 2025-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.